DMT
Cava soars in stock market debut — hits $4.7B valuation
Mediterranean restaurant chain Cava Group notched a valuation of $4.7 billion in a stellar market debut on Thursday, signaling the IPO market was gaining…
Mediterranean restaurant chain Cava Group notched a valuation of $4.7 billion in a stellar market debut on Thursday, signaling the IPO market was gaining momentum after a lull in 2022.
Shares opened at $42 apiece on the NYSE, nearly double the IPO price of $22, last up 89%. Cava sold about 14.4 million shares in the offering, raising $318 million.
Investors are warming up to IPOs this year after a volatility-fueled 2022 curbed appetite for new listings and fueled a risk-off sentiment.
“The fact that CAVA is unprofitable and generating this level of interest is certainly an important development,” Matthew Kennedy, senior IPO market strategist at Renaissance Capital told Reuters, adding that IPO activity will gradually normalize in the second half of the year.
Last month, Johnson & Johnson’s consumer health business, Kenvue, completed the largest IPO since Rivian Automotive listed in 2021.
The fast-casual restaurant industry has posted strong sales in recent months despite concerns of a looming recession in the United States.
“We think the markets are always welcoming long-term sustainable growth stories, especially category defining brands, as we try and define the Mediterranean category,” Cava co-founder and CEO Brett Schulman said.
So far this year, listed peers such as Chipotle Mexican Grill and Shake Shack have risen more than 48% each, outpacing the rise in shares of fast-food brands McDonald’s and Restaurant Brands International.
Cava was founded by three friends with Greek roots — Ted Xenohristos, Ike Grigoropoulos and Dimitri Moshovitis — and opened its first restaurant Cava Mezze in Rockville in 2006.
It started selling its signature dips and spreads in local grocery stores within two years of establishing its first outlet.
JPMorgan, Jefferies and Citigroup were the joint lead book-running managers for Cava’s offering.
The post Cava soars in stock market debut — hits $4.7B valuation appeared first on REPORT DOOR.
dimitri-
Psilocybin1 week ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics7 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics6 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics7 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Law & Regulation5 days ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Ketamine6 days ago
DEA poised to move cannabis to Schedule III
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics6 days ago
Behold! A New Mushroom Emoji Has Arrived!